VivoSeq
Other

Immunity

0

Pipeline Programs↗

6

Active Trials↗

3

Companies Involved↗

Immunity is an early-stage landscape with 0 programs across 3 companies. The most active players are Beijing Minhai Biotechnology Co., Ltd, Sanofi, Sinovac Biotech Co., Ltd.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

96/100

Attrition Rate

2/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Beijing Minhai Biotechnology Co., Ltd

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalSinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

41

clinical trials

Completed27 · 66%
Unknown status7 · 17%
Not yet recruiting3 · 7%
Active, not recruiting2 · 5%
Terminated1 · 2%
Recruiting1 · 2%

Clinical Trials

Trial Activity

41 trials

Innate Immunity Stimulation Via TLR9 in Early AD
Recruiting·NNYU Langone Health·Phase 1·NCT05606341·18 enrolled
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT04745559·26 enrolled
Salt-Sensitivity and Immunity Cell Activation
Active, not recruiting·VVanderbilt University Medical Center·Phase 1/2·NCT03753204·20 enrolled
Intranasal LAIV Mucosal Immunity Examination
Not yet recruiting·UUniversity of Maryland, Baltimore·Phase 4·NCT07093281·25 enrolled
Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure
Not yet recruiting·UUniversitätsklinikum Hamburg-Eppendorf·Phase 3·NCT05959421·70 enrolled
A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants
Not yet recruiting·FFidec Corporation·Phase 3·NCT07010822·740 enrolled
Immunity Against AAV in Crigler Najjar Patient
Completed·GGenethon·N/A·NCT02302690·49 enrolled
Cell Mediated Immunity in Older Adults
Completed·VVanderbilt University·N/A·NCT01189123·105 enrolled
Effect of Refnot on Immunity in Cancer Patients
Completed·RRefnot-Pharm Ltd·Phase 2·NCT05898451·55 enrolled
Ontogeny of Measles Immunity in Infants
Completed·SStanford University·N/A·NCT00240916·750 enrolled
BARDA Securing Anthrax Immunity For the Elderly
Completed·Biomedical Advanced Research and Development Authority·Phase 2·NCT03518125·305 enrolled
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years
Completed·BBeijing Minhai Biotechnology Co., Ltd·Phase 4·NCT06210737·621 enrolled
Persistence of IPV Immunity
Completed·TTribhuvan University Teaching Hospital, Institute Of Medicine.·Phase 4·NCT03723837·502 enrolled
Immunity Persistence After Abridged Intradermal Rabies PEP
Completed·IInstitut Pasteur·N/A·NCT04829630·180 enrolled
Reconstitution of HIV-specific Immunity Against HIV
Completed·GGuangzhou 8th People's Hospital·Phase 1·NCT02563509·30 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)